MedPath

OliPass Corporation

🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:2

Trial Phases

3 Phases

Early Phase 1:1
Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Early Phase 1
1 (33.3%)
Phase 1
1 (33.3%)
Phase 2
1 (33.3%)

Study of OLP-1002 Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in Hip and/or Knee Joint

Phase 2
Completed
Conditions
Osteoarthritis
Interventions
First Posted Date
2022-01-31
Last Posted Date
2024-05-10
Lead Sponsor
OliPass Corporation
Target Recruit Count
134
Registration Number
NCT05216341
Locations
🇦🇺

Northern Beaches Clinical Research, Brookvale, New South Wales, Australia

🇦🇺

Novatrials, Kotara, New South Wales, Australia

🇦🇺

Sutherland Shire Clinical Research, Miranda, New South Wales, Australia

and more 2 locations

OLP-1002 is Being Studied in the Treatment of Pain.

Early Phase 1
Completed
Conditions
Pain
First Posted Date
2018-12-03
Last Posted Date
2021-08-26
Lead Sponsor
OliPass Corporation
Target Recruit Count
116
Registration Number
NCT03760913
Locations
🇬🇧

Leeds CRU, Leeds, United Kingdom

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.